Research Article

Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI

Table 1

Echocardiographic parameters of the left ventricle pre- and posttreatment.

GroupLVEF (%)
Pretreatment
LVEF (%)
Posttreatment
EDV (mL)
Pretreatment
EDV (mL)
Posttreatment
ESV (mL)
Pretreatment
ESV (mL)
Posttreatment

EVs29.7
(19.9/42)
33.8
(24.3/56.7)
0.60
(0.45/0.76)
1.02
(0.71/1.35)
0.41
(0.27/0.60)
0.72
(0.31/1.02)
CD133+32.3 (20.2/38.6)34.7
(14.8/54.8)
0.62
(0.44/0.75)
0.88
(0.54/1.32)
0.45
(0.27/0.56)
0.59
(0.25/1.12)
Vehicle29.3
(26.5/42.4)
33.5
(23.1/44.5)
0.67
(0.44/0.84)
1.12
(0.67/1.36)
0.46
(0.31/0.60)
0.68
(0.44/0.98)
Control60.4
(58.3/64.7)
65.3
(61.4/70.8)
0.49
(0.42/0.60)
0.57
(0.52/0.61)
0.19
(0.16/0.24)
0.18
(0.17/0.23)

LVEF: left ventricular ejection fraction; EDV: end-diastolic volume; ESV: end-systolic volume; EVs: transplanted with expanded CD133+ cell-derived EVs; CD133+: transplanted with expanded CD133+ cells; vehicle: treated with PBS; control: healthy animals ( to 8 per group). Data are presented as median (minimum/maximum). Significant difference between pre- and posttreatment moments of each group ().